Utama › Polsitemia Vera › California
Kajian klinikal Polsitemia Vera di California
6 kajian untuk Polsitemia Vera sedang mencari peserta di lokasi di California.
Bandar di California
Teks kajian rasmi (Bahasa Inggeris)
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- UCLA Ronald Reagan Medical Center, Los Angeles
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07469891A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
- Stanford Cancer Institute Palo Alto, Palo Alto
- dan 1 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06661915Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- City of Hope-Lennar Foundation Cancer Center, Irvine
- Usc Norris Comprehensive Cancer Center, Los Angeles
- UCLA Medical Hematology & Oncology, Los Angeles
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jul 2026 · NCT07441694Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Mac 2026 · NCT06063486Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
- Emad Ibrahim, MD, Inc, Redlands
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Mac 2026 · NCT06093672An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
- University of California, Irvine, Irvine
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Mac 2026 · NCT05123365Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.